DrugPatentWatch Database Preview
KYPROLIS Drug Profile
When do Kyprolis patents expire, and when can generic versions of Kyprolis launch?
Kyprolis is a drug marketed by Onyx Therap and is included in one NDA. There are eleven patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and eighty-eight patent family members in thirty-six countries.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.
Summary for KYPROLIS
| International Patents: | 188 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 55 |
| Clinical Trials: | 54 |
| Patent Applications: | 179 |
| Drug Prices: | Drug price information for KYPROLIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KYPROLIS |
| DailyMed Link: | KYPROLIS at DailyMed |
Generic Entry Opportunity Date for KYPROLIS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KYPROLIS
| Drug Class | Proteasome Inhibitor |
| Mechanism of Action | Proteasome Inhibitors |
Synonyms for KYPROLIS
| (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide |
| (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide |
| (2S)-N-[(1S)-1-benzyl-2-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]amino]-2-oxo-ethyl]-4-methyl-2-[[(2S)-2-[(2-morpholinoacetyl)amino]-4-phenyl-butanoyl]amino]pentanamide |
| (Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide |
| (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phenylalaninamide |
| (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide |
| (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide |
| 72X6E3J5AR |
| 868540-17-4 |
| AB0008111 |
| AB01565867_02 |
| AC-27051 |
| AKOS025401910 |
| AN-217 |
| AOB87759 |
| AS-17059 |
| BC251806 |
| BDBM50277889 |
| BLMPQMFVWMYDKT-NZTKNTHTSA-N |
| C40H57N5O7 |
| Carfilzomib |
| Carfilzomib (JAN/USAN/INN) |
| Carfilzomib (PR-171) |
| Carfilzomib [USAN:INN] |
| Carfilzomib?PR-171?/Kyprolis |
| Carfilzomib(PR171) |
| CAS-868540-17-4 |
| CHEBI:65347 |
| CHEMBL451887 |
| CS-0984 |
| CS-W004540 |
| D00UVA |
| D08880 |
| DB08889 |
| DSSTox_CID_28616 |
| DSSTox_GSID_48690 |
| DSSTox_RID_82886 |
| DTXSID4048690 |
| FT-0696769 |
| GTPL7420 |
| HY-10455 |
| J-501773 |
| KB-75946 |
| KS-00000SR1 |
| Kyprolis (TN) |
| L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)- |
| MFCD11040997 |
| MLS006011102 |
| MolPort-027-950-907 |
| N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide |
| NCGC00249613-01 |
| NCGC00249613-02 |
| NCGC00249613-03 |
| ONO-7057 |
| PR 171 |
| PR-171 |
| PX-171-007 |
| QCR-96 |
| RL05381 |
| S-7798 |
| s2853 |
| SC-91032 |
| SCHEMBL85165 |
| SMR004660024 |
| SR-01000941582 |
| SR-01000941582-1 |
| Tox21_113079 |
| Tox21_113079_1 |
| UNII-72X6E3J5AR |
| Y0441 |
| ZINC49841054 |
US Patents and Regulatory Information for KYPROLIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for KYPROLIS
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 30 mg/vial | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | ➤ Sign Up |
International Patents for KYPROLIS
Supplementary Protection Certificates for KYPROLIS
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016010,C1781688 | Lithuania | ➤ Sign Up | PRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 16/013 | Ireland | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 90013-6 | Sweden | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
